How Big Data Is Accelerating EXUMA Biotech In The Race To Rapid CAR-T Therapy
Source: bioprocessonline.com In 2021, EXUMA Biotech plans to take its Rapid Point of Care (rPOC) platform to the clinic in hopes of proving out the viability of 6-hour vein-to-vein CAR T therapy administration in cancer patients. Gregory Frost, Ph.D., is perhaps best known for his 15-year tenure at Halozyme Therapeutics, the biopharma he co-founded in 1999 Read More